Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa

Authors
Citation
F. Nuwaha, Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa, E AFR MED J, 75(9), 1998, pp. 520-527
Citations number
51
Categorie Soggetti
General & Internal Medicine
Journal title
EAST AFRICAN MEDICAL JOURNAL
ISSN journal
0012835X → ACNP
Volume
75
Issue
9
Year of publication
1998
Pages
520 - 527
Database
ISI
SICI code
0012-835X(199809)75:9<520:CFTIHI>2.0.ZU;2-8
Abstract
Objective: To examine the role of chemoprophylaxis as a public health strat egy for the control of tuberculosis in sub-Saharan Africa. Data sources: published literature regarding efficacy, cost-effectiveness a nd operational feasibility of chemoprophylaxis programmes, Study selection: Studies mainly published from countries in sub-Saharan Afr ica and other low income countries. Data extraction: Manual search of journals and computer search of data base s. Data synthesis: Latent infection with tuberculosis among adults in sub-Saha ran Africa is more than 50% and HIV infection in the same age group is more than 10%, TB treatment programmes in the region are overwhelmed by increas ing numbers of clinical TB. The efficacy and safety of isoniazid preventing TB among HIV infected individuals has been demonstrated in various studies . Though data on its cost-effectiveness is limited, computer modelling show that chemoprophylaxis for HIV associated tuberculosis is more cost-effecti ve than chemotherapy. A national chemoprophylaxis programme need to achieve three broad objectives: HIV testing and counselling; tuberculin testing an d exclusion of active TB; and to achieve high enough compliance rates. Thes e objectives are hest achieved by co-operation between National TB and AIDS control programmes. Conclusions: Because chemoprophylaxis for HIV associated TB makes economic and epidemiological sense, large national programmes should be initiated in sub-Saharan Africa. Operational research is necessary to define the best w ays to deliver chemoprophylaxis to the majority of the HIV infected persons and to test the cost-effectiveness of chemoprophylaxis in established nati onal programmes.